Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024

ARDX 10.17.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-10-31
Name of Upcoming Event:unknown
Full Press ReleaseSEC FilingsOur ARDX Tweets

About Gravity Analytica

Recent News

  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
  • 01.06.2025 - Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.22.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.16.2025 - 144 Report of proposed sale of securities
  • 01.13.2025 - 8-K Current report
Conference call scheduled for 4:30 p.m. Eastern Time

WALTHAM, Mass.,Oct. 17, 2024(GLOBE NEWSWIRE) --Ardelyx, Inc.(Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call onThursday, October 31, 2024, at4:30 p.m. Eastern Timeto discuss financial results and provide a business update from the third quarter of 2024.

To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into theArdelyxcall. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website atwww.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.

AboutArdelyxArdelyxwas founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs.Ardelyxhas two commercial products approved inthe United States, IBSRELA®(tenapanor) and XPHOZAH®(tenapanor).Ardelyxhas agreements for the development and commercialization of tenapanor outside of theU.S.Kyowa Kirin commercializes PHOZEVEL®(tenapanor) for hyperphosphatemia inJapan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted inChinawith Fosun Pharma. Knight Therapeutics commercializes IBSRELA inCanada. For more information, please visithttps://ardelyx.com/and connect with us onX (formerly known as Twitter),LinkedInandFacebook.

Investor and Media Contacts:Caitlin Lowieclowie@ardelyx.com

Primary Logo

Source: Ardelyx, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com